FACL6 Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9UKU0 |
---|---|
Other Accession | ACSL6_HUMAN |
Clone Names | 3092106 |
Gene ID | 23305 |
---|---|
Other Names | Long-chain-fatty-acid--CoA ligase 6, Long-chain acyl-CoA synthetase 6, LACS 6, ACSL6, ACS2, FACL6, KIAA0837, LACS5 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP2537b was selected from the Center region of human FACL6 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | ACSL6 (HGNC:16496) |
---|---|
Function | Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoA for both synthesis of cellular lipids, and degradation via beta-oxidation (PubMed:22633490, PubMed:24269233). Plays an important role in fatty acid metabolism in brain and the acyl- CoAs produced may be utilized exclusively for the synthesis of the brain lipid. |
Cellular Location | Mitochondrion outer membrane; Single-pass type III membrane protein. Peroxisome membrane; Single-pass type III membrane protein. Microsome membrane; Single-pass type III membrane protein. Endoplasmic reticulum membrane; Single-pass type III membrane protein |
Tissue Location | Expressed predominantly in erythrocyte precursors, in particular in reticulocytes, fetal blood cells derived from fetal liver, hemopoietic stem cells from cord blood, bone marrow and brain |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
FACL6 is involved in activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. It plays an important role in fatty acid metabolism in brain and the acyl-CoAs produced may be utilized exclusively for the synthesis of the brain lipid. FACL6 is expressed predominantly in erythrocyte precursors, in particular in reticulocytes, fetal blood cells derieved from fetal liver, haemopoietic stem cells from cord blood, bone marrow, and brain. Expression is low at earlier stages of erythroid development but is very high in reticulocytes. This protein is involved in myelodysplastic syndrome (MDS) with basophilia, acute myelogenous leukemia (AML) with eosinophilia, and acute eosinophilic leukemia (AEL). It is characterized by a chromosomal translocation t(5;12)(q31;p13) that involves ETV6 and ACSL6.
References
Yagasaki, F., et al., Genes Chromosomes Cancer 26(3):192-202 (1999).Nagase, T., et al., DNA Res. 5(6):355-364 (1998).Malhotra, K.T., et al., Biochem. J. 344 Pt 1, 135-143 (1999).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.